triple hormone receptor agonist retatrutide for obesity metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide: A Triple Agonist Shaping
Description
The imaging was cancelled because of the risk of aspiration during anesthesia
It works through GLP-1 receptors to regulate appetite and blood sugar
It does not automatically mean the medicine is not working
Respiratory rates were monitored throughout, and respiration was maintained within the range of 180220 breaths per minute
Safety cannot be guaranteed
Weight loss is not just about appearanceit is about health, energy, and confidence
